Lung cancer has one of the worst prognosis among the different cancers, especially when detected at a late stage. According to figures from the NHS, in the UK alone around 44,500 people will be diagnosed with lung cancer this year and 35,200 will die. If detected at stage 1, the five-year survival rate for lung cancer is 54%, but this drops to just 4% if the cancer is detected at stage 4.
Owlstone Medical, a Cambridge-based diagnostics company, is aiming to bring to market a breathalyzer test that can improve lung cancer outcomes by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?